November 12- EOD

Well, I think it was more of the same in the sector writ large with the biggest news obviously being SRPT, which I will touch on below. I was surprised to see the small caps hold up as well as they did on the news and that is a slight positive for the sector going […]

October 23-EOD

Not a lot of news in terms of data, although we saw BMY, AMGN, and LLY report earnings. The biotech sector was not as much of a relative underperformer today. Of course, it was still red and weak but today it was red and weak in the context of a broader market selloff. Volumes seemed […]

October 17- EOD

A mixed day in the market which was nice to see a day in which not all stocks were moving in the same direction. Obviously had some stock specific news with AMRN and the PSDV PDUFA and some more general biotech news. 1. AMRN was the stock of the day with about a 67% haircut […]

October 16- EOD

With the approach of an end (as temporary as it is likely to be) of the stalemate in Washington you thought we would be approaching the end of the macro driven market. While I think that is likely true, we still are going to have a knee jerk relief rally before it settles back down […]

October 8- Mid Day

While I wanted some more news from the biotech sector this was not exactly what I was planning. I discuss my thoughts on ARIA in an article on the street, so I will not belabor it more here. There are a couple of broader points that I think are interesting in light on today’s action. […]

September 30-EOD

There was certainly some interesting news and action today. The market was weak early but biotech was much more mixed than one would have expected. It is good to see those pockets of strength during the broad market sell offs. 1. ARIA was interesting on two levels: AP113 data and Iclusig sales. There was additional […]

September 30-EOD

There was certainly some interesting news and action today. The market was weak early but biotech was much more mixed than one would have expected. It is good to see those pockets of strength during the broad market sell offs. 1. ARIA was interesting on two levels: AP113 data and Iclusig sales. There was additional […]

September 30-EOD

There was certainly some interesting news and action today. The market was weak early but biotech was much more mixed than one would have expected. It is good to see those pockets of strength during the broad market sell offs. 1. ARIA was interesting on two levels: AP113 data and Iclusig sales. There was additional […]

September 4- EOD

There was some nice action in biotech land today despite not being particularly busy in terms of news. There was some interesting stock specific action and the sector was a mixed bag. Stocks without specific news tended to underperform but not universally so. The next couple of months will be interesting as volume will likely […]

August 2- EOD

Fairly quiet day after a rather eventful week, so it is nice to have a little less to write about as we ease into the weekend. 1. I wanted to spend a little time talking about why I bought TTPH earlier this week with the TSRX proceeds. First, I wanted to keep most of the […]

July 31- EOD

Well, it was certainly a news filled evening and it will take a couple of days to sort through it all, so today will be a first cut. In general it was an odd day in biotech as there were certainly pockets of outperformance but the sector in general seemed weak despite the strength in […]

July 19- EOD

Really seemed like a quiet summer day to end the week. Not much to talk about but a couple of follow up notes from earlier discussions. 1. To continue from my MYGN notes from yesterday, it was confirmed from LH that they will be in the BRCA market. This just builds on the bear case […]

July 15- EOD

Well, there was not a lot of news out there in biotech land but oddly there is a lot I want to talk about and will work through it over the next couple of days. 1. ARIA Iclusig prescriptions came in weak again with new prescriptions down 26% and only a 9% gain in continuing […]

June 27- EOD

I thought today would be a much better day in the market for biotechs and they looked strong early but did not seem to have any real follow through. Not that it was a bad day; rather, it seemed to show more strength early. Still some stock specific stories to talk about. 1. CELG signed […]

June 14- Midday

This is midday today as I will be out of my office for the rest of the day. So an early surprise. A very odd day today in the market. Biotechs really seemed to lag for some reason even when the market was not a real drag. Let’s see how we end the day. 1. […]

May 24 – End Of Day Biotech Wrap-up

Really another slow day entering into the long weekend. From my perspective, there were really only two really interesting moves. 1. AVEO was a bit of a shocker. AVEO disclosed in a filing that Astellas will no longer fund tivozanib in RCC and would not seek approval in the EU. There are still some other […]

May 22 – End Of Day Biotech Wrap-up

While the market got some intraday whipsaw action, it seemed generally good and biotechs did well- early. We had a late day sell-off with biotechs seeming to do better than the market in general. 1. It seems like just yesterday I was positive but cautious on ARIA because it was still making lower high and […]

May 20th – End Of Day Biotech Wrap-up

Outside of a not completely unexpected merger, it was a relatively quite start to the week. As has been par for the course, ASCO oncology stocks tended to be weak but not in a significant manner. Perhaps we are having the quite before the storm. 1. PPHM announced its agreement with the FDA on a […]

Week’s Option Activity (5/13~5/17)

The following stocks had notable activity in their options during the past week: $OPTR (5/13): 2,250 SEP 17.50 strike Calls were sold against equal number of purchased JUN 12.5 Puts (stock @ $12.81) for total debit of 0.85 or $191,250. Trade most likely a hedge of an existing long stock position. $MNTA (5/13): 926 JAN14 […]